← Human Trials & Peer-Reviewed Studies
Effect of meal size and texture on gastric pouch emptying and glucagon-like peptide 1 after gastric bypass surgery.
Plain-language guide to PMID 29055668 (2017): randomized controlled trial of Glucagon.
Key Facts
- PMID
- 29055668
- Journal
- Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Stano S et al. (8 authors)
- DOI
- 10.1016/j.soard.2017.09.004
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Glucagon.
Roux-en-Y gastric bypass (RYGB) accelerates gastric pouch emptying, enhances postprandial glucagon-like peptide 1 (GLP-1) and insulin, and lowers glucose concentrations.
Who Took Part
By PubMed's age tags, the people studied were young adults and adults, both men and women.
In this prospective study, 32 RYGB candidates were enrolled and randomized to L or S groups before gastric bypass.
Each subject received an L or S 600-kcal single meal (SM) administered at hour 0 or three 200-kcal minimeals administered at hours 0, 2, and 4 on 2 separate days.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Twenty-one patients were retested 1 year after RYGB.
Outcome measures included gastric pouch emptying, glucose, insulin, and GLP-1; hunger, fullness, and stomach discomfort were measured by visual analogue scale.
What Was Measured
The subject headings attached to it are Blood Glucose, Diet, Gastric Bypass, Gastric Emptying, Glucagon-Like Peptide 1, Insulin and Meals.
The authors tagged it with the keywords GLP-1, Meal size and Meal texture.
What This Means in Plain Language
The paper is a randomized study of Glucagon.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2017 (Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery), a journal based in United States.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.